Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells [CRISPRoff]
RNA-seq (gene expression) · human · 28 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 28 samples: 8 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE327133_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1449495 and SRA study SRP689636. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 16 samples.
How we read this: 8 replicated groups read from 28 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9649068 Donor1 untreated human monocyte-derived macrophages
- GSM9649069 Donor1 human monocyte-derived macrophages treated with non-target eVLP
- GSM9649070 Donor1 human monocyte-derived macrophages treated with CD81-targeting eVLP
- GSM9649071 Donor1 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA1 Donor1 human monocyte-d…
- GSM9649072 Donor1 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA2 Donor1 human monocyte-d…
- GSM9649073 Donor1 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA1 Donor1 human monocyte-d…
- GSM9649074 Donor1 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA2 Donor1 human monocyte-d…
- GSM9649075 Donor2 untreated human monocyte-derived macrophages
- GSM9649076 Donor2 human monocyte-derived macrophages treated with non-target eVLP
- GSM9649077 Donor2 human monocyte-derived macrophages treated with CD81-targeting eVLP
- GSM9649078 Donor2 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA1 Donor2 human monocyte-d…
- GSM9649079 Donor2 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA2 Donor2 human monocyte-d…
- GSM9649080 Donor2 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA1 Donor2 human monocyte-d…
- GSM9649081 Donor2 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA2 Donor2 human monocyte-d…
- GSM9649082 Donor3 untreated human monocyte-derived macrophages
- GSM9649083 Donor3 human monocyte-derived macrophages treated with non-target eVLP
- GSM9649084 Donor3 human monocyte-derived macrophages treated with CD81-targeting eVLP
- GSM9649085 Donor3 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA1 Donor3 human monocyte-d…
- GSM9649086 Donor3 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA2 Donor3 human monocyte-d…
- GSM9649087 Donor3 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA1 Donor3 human monocyte-d…
- GSM9649088 Donor3 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA2 Donor3 human monocyte-d…
- GSM9649089 Donor4 untreated human monocyte-derived macrophages
- GSM9649090 Donor4 human monocyte-derived macrophages treated with non-target eVLP
- GSM9649091 Donor4 human monocyte-derived macrophages treated with CD81-targeting eVLP
- GSM9649092 Donor4 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA1 Donor4 human monocyte-d…
- GSM9649093 Donor4 human monocyte-derived macrophages treated with CD45-targeting eVLP sgRNA2 Donor4 human monocyte-d…
- GSM9649094 Donor4 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA1 Donor4 human monocyte-d…
- GSM9649095 Donor4 human monocyte-derived macrophages treated with CD14-targeting eVLP sgRNA2 Donor4 human monocyte-d…
- GSE327354 Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells [RNA-seq Exp3] 18 samples shares crispr, engineering, virus-like, particles, screening, targeted, primary
- GSE327357 Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells [RNA-Seq Exp1] 14 samples shares crispr, engineering, virus-like, particles, screening, targeted, primary
- GSE327352 Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells [RNA-seq Exp2] 12 samples shares crispr, engineering, virus-like, particles, screening, targeted, primary
- GSE327424 Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells 86 samples shares crispr, engineering, virus-like, particles, screening, targeted, primary
- GSE318716 In vivo engineering of hematopoietic stem cells by targeted lipid nanoparticles within humanized mice 21 samples shares engineering, particles, targeted
- GSE301632 Genome-wide CRISPR-Cas9 knockout screening identifies NUDCD2 depletion as sensitizer for bortezomib, carfilzomib and ixazomib in multiple myeloma. 27 samples shares crispr, screening
- GSE283574 Single-Cell Cas12a Platform for Screening and CRISPRi 26 samples shares crispr, screening
- GSE303100 Dissecting Resistance to CDK4/6 Inhibition in Experimental Glioma via Genome-wide CRISPR-Cas9 Screening 24 samples shares crispr, screening
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.